spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  IIb/IIIa inhibitor 

 HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA Corp. Limited to Acquire Specialty Pharmaceutical Company Correvio Pharma Corp.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Aug 2017
Cardiome Provides U.S. Regulatory Update For BRINAVESS
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 21 Jun 2017
Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Jun 2017
Cardiome Announces Commercial Launch of BRINAVESS(R) (Vernakalant Hydrochloride) in Canada
Biopharmaceuticals Cardiology Product Launch
 HSMN NewsFeed - 3 Mar 2017
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 8 Dec 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 29 Nov 2016
Cardiome Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch
Biopharmaceuticals Reimbursement Product Launch
 HSMN NewsFeed - 12 May 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
Biopharmaceuticals Cardiology Product Launch
 HSMN NewsFeed - 9 Jul 2015
The Medicines Company Authorizes Generic Launch of ANGIOMAX(R) (bivalirudin)
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 18 Dec 2014
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 9 Oct 2013
First Patient Enrolled in Phase III Trial Evaluating The Medicines Company's Angiomax(R) (Bivalirudin) in Patients Undergoing Peripheral Endovascular Procedures
Biopharmaceuticals Interventional
 HSMN NewsFeed - 30 Aug 2013
ITC Acquires Accumetrics to Form Leading POC Cardiovascular Diagnostics Business
Diagnostics Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 31 Jul 2013
New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on Findings of Reduced Rate of Stent Thrombosis With BRILINTA (ticagrelor)
Biopharmaceuticals Devices Interventional Cardiology
 HSMN NewsFeed - 25 Oct 2011
Lilly Announces Withdrawal of Xigris(R) Following Recent Clinical Trial Results
Biopharmaceuticals
 HSMN NewsFeed - 11 May 2011
Accumetrics Signs National Distribution Agreement with Cardinal Health
Diagnostics Personalized Medicine Cardiology Distribution
 HSMN NewsFeed - 9 Mar 2011
2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery
Diagnostics Biopharmaceuticals Surgery Cardiology
 HSMN NewsFeed - 16 Nov 2010
GRAVITAS Trial Shows That a Uniform Treatment Strategy of Doubling the Standard Dose of Plavix Does Not Improve Outcomes Post-PCI
Diagnostics Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 15 Mar 2010
Inadequate Response to Clopidogrel Leads to Higher Incidence of Major Adverse Cardiac Events in Patients Who have Undergone PCI
Biopharmaceuticals Diagnostics Cardiology
 HSMN NewsFeed - 1 Dec 2009
The Medicines Company Receives European Approval for Angiox(R) (Bivalirudin) for Use in Heart Attack Patients Undergoing Emergency Heart Procedures
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 31 Aug 2009
sanofi-aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 May 2009
Accumetrics, Inc. Announces European Distribution Channels for France, Austria, Switzerland, Netherlands, Belgium and Luxembourg
Diagnostics Cardiology Distribution
 HSMN NewsFeed - 2 Sep 2008
New Data Shows Anticlotting Medicine, AGGRASTAT(R), Lowers Incidence of Heart Attack, in Patients Who Respond Poorly to Aspirin or Clopidogrel, after Elective Coronary Angioplasty
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Aug 2008
ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 May 2008
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 22 May 2008
Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted in Improved Survival Rates in the Most Severe Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Mar 2008
Angiomax Demonstrated Improved Outcomes in Acute Heart Attack Patients Undergoing Primary Angioplasty Independent of Individual Risk Factors
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 29 Jan 2008
The Medicines Company's Angiox(R) Receives European Authorization for Expanded Use in Patients with Acute Coronary Syndromes (ACS)
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 4 Dec 2007
Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Oct 2007
Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Sep 2007
FDA Accepts sNDA for Expanded Use of Angiomax(R) (bivalirudin)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 2 Sep 2007
Angiox(R) (Bivalirudin) Alone Reduced Early Bleeding and Resulted in Similar One-Year Mortality Compared to Heparins Plus GP IIb/IIIa Combination Therapy in ACS Patients Undergoing Angioplasty
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Aug 2007
The Medicines Company Submits Angiomax(R) (Bivalirudin) sNDA to Expand Label to Include ACUITY Data
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Jul 2007
Positive Aggrastat(R) Results Versus Integrilin(R) Featured in American Heart Journal
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 2 Jul 2007
The Medicines Company Reacquires Angiox(R) (Bivalirudin) Rights in Europe from Nycomed
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Mar 2007
ACUITY One-Year Findings Meet All Primary Endpoints in Favor of Angiomax(R) (Bivalirudin) Alone Treatment Group
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Nov 2006
The New England Journal of Medicine Publishes Angiomax(R) (Bivalirudin) ACUITY Trial Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 14 Nov 2006
Medicure Announces New AGGRASTAT(R) Data at 2006 Scientific Sessions of the American Heart Association
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 11 Oct 2006
Medicure Announces Launch of U.S. Sales Organization
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Aug 2006
Medicure Acquires U.S. Rights to Aggrastat'R' from MGI PHARMA, INC.
Biopharmaceuticals Cardiology Acquisitions
 HSMN NewsFeed - 6 Apr 2006
ARIXTRA(R) Significantly Reduced Major Bleeding Compared to LOVENOX(R) in a Study of Patients With Acute Coronary Syndromes
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Mar 2006
Angiomax(R) (bivalirudin) Monotherapy Superior to Heparins Plus GP IIb/IIIa Combination for Net Clinical Outcome in ACUITY Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 10 Feb 2006
Chairman of Cleveland Clinic Department of Cardiovascular Medicine Resigns
Cardiology Personnel
Return to NewsFeed  

 Additional items found! 30

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 30 additional stories matching:
IIb/IIIa inhibitor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.